Updating results

6574 results Sort: Relevance | Date

Mepolizumab for treating severe refractory eosinophilic asthma (TA431)

Evidence-based recommendations on mepolizumab (Nucala) for treating severe refractory eosinophilic asthma in adults

Technology appraisal guidance Published January 2017

Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430)

Evidence-based recommendations on sofosbuvir–velpatasvir (Epclusa) for treating chronic hepatitis C in adults

Technology appraisal guidance Published January 2017

Cerebral palsy in under 25s: assessment and management (NG62)

Evidence-based recommendations on diagnosing, assessing and managing cerebral palsy in children and young people under 25

NICE guideline Published January 2017

Antimicrobial stewardship: changing risk-related behaviours in the general population (NG63)

Evidence-based recommendations on changing people's behaviour (including use of antibiotics and preventing infection) to reduce antimicrobial resistance

NICE guideline Published January 2017

Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)

Evidence-based recommendations on pomalidomide (Imnovid) for multiple myeloma previously treated with lenalidomide and bortezomib in adults

Technology appraisal guidance Published January 2017

Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)

Evidence-based recommendations on pembrolizumab (Keytruda) for locally advanced or metastatic PD-L1-positive non-small-cell lung cancer (NSCLC) in adults

Technology appraisal guidance Published January 2017

Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)

Evidence-based recommendations on certolizumab pegol (Cimzia) for treating severe active rheumatoid arthritis in adults who have had a tumour necrosis factor

Technology appraisal guidance Published October 2016

Physical health of people in prison (NG57)

Evidence-based recommendations on assessing, diagnosing and managing physical health problems of people in prisons or young offenders' institutions

NICE guideline Published November 2016

Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)

Evidence-based recommendations on cobimetinib (Cotellic) with vemurafenib (Zelboraf) for unresectable or metastatic melanoma in adults with a BRAF V600

Technology appraisal guidance Published October 2016

Nivolumab for previously treated advanced renal cell carcinoma (TA417)

Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma (RCC/kidney cancer) in adults

Technology appraisal guidance Published November 2016

Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)

Evidence-based recommendations on crizotinib (Xalkori) for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults

Technology appraisal guidance Published December 2016

Blood transfusion (QS138)

Evidence-based statements to deliver quality improvements in the general principles of blood transfusion in adults, young people and children over 1 year old

Quality standard Published December 2016

Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)

Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events such as heart attacks or stroke after myocardial infarction (MI)

Technology appraisal guidance Published December 2016

End of life care for infants, children and young people with life-limiting conditions: planning and management (NG61)

Evidence-based recommendations on managment of end of life care for infants, children and young people (aged 0–17 years) with life-limiting conditions

NICE guideline Published December 2016

Mental wellbeing and independence for older people (QS137)

Evidence-based statements to deliver quality improvements to maintain or improve the mental wellbeing and independence of people aged 65 or over

Quality standard Published December 2016

Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)

Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and imatinib (Glivec) for untreated chronic myeloid leukaemia in adults

Technology appraisal guidance Published December 2016

Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)

Evidence-based recommendations on dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant/intolerant chronic myeloid leukaemia in adults

Technology appraisal guidance Published December 2016

Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)

Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic breast cancer after 2 or more types of chemotherapy

Technology appraisal guidance Published December 2016

Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)

Evidence-based recommendations on pertuzumab (Perjeta) for HER2-positive breast cancer in adults

Technology appraisal guidance Published December 2016

HIV testing: increasing uptake among people who may have undiagnosed HIV (NG60)

Evidence-based recommendations on increasing the uptake of testing among people who may have undiagnosed HIV

NICE guideline Published December 2016

Coexisting severe mental illness and substance misuse: community health and social care services (NG58)

Evidence-based recommendations on improving services for people aged 14 and above with coexisting severe mental illness and substance misuse

NICE guideline Published November 2016

Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)

Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy

Technology appraisal guidance Published December 2016

Low back pain and sciatica in over 16s: assessment and management (NG59)

Evidence-based recommendations on assessing and managing low back pain and sciatica in people aged 16 and over

NICE guideline Published November 2016

Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)

Evidence-based recommendations on dapagliflozin (Forxiga) given with 2 other drugs for treating type 2 diabetes in adults

Technology appraisal guidance Published November 2016

Apremilast for treating moderate to severe plaque psoriasis (TA419)

Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published November 2016

Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)

Evidence-based recommendations on necitumumab (Portrazza) for untreated advanced or metastatic squamous non-small-cell lung cancer (NSCLC) in adults

Technology appraisal guidance Published September 2016

Transition between inpatient mental health settings and community or care home settings (NG53)

Evidence-based recommendations on transition between inpatient mental health settings and community or care home settings

NICE guideline Published August 2016

Sepsis: recognition, diagnosis and early management (NG51)

Evidence-based recommendations on the recognition, diagnosis and early management of sepsis (blood poisoning / septicaemia) in all populations

NICE guideline Published July 2016

Harmful sexual behaviour among children and young people (NG55)

Evidence-based recommendations on assessing children and young people who display harmful sexual behaviour, including those on remand or serving..

NICE guideline Published September 2016

Multimorbidity: clinical assessment and management (NG56)

Evidence-based recommendations on the clinical assessment and management of multimorbidity (multiple long-term conditions) in adults

NICE guideline Published September 2016

Early years: promoting health and wellbeing in under 5s (QS128)

Evidence-based statements to deliver quality improvements in services to support the health, social and emotional wellbeing of children under 5

Quality standard Published August 2016

Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)

Evidence-based recommendations on talimogene laherparepvec (Imlygic) for treating unresectable metastatic melanoma in adults

Technology appraisal guidance Published September 2016

Pegaspargase for treating acute lymphoblastic leukaemia (TA408)

Evidence-based recommendations on pegaspargase (Oncaspar) for treating acute lymphoblastic leukaemia

Technology appraisal guidance Published September 2016

Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (TA407)

Evidence-based recommendations on secukinumab (Cosentyx) for ankylosing spondylitis (spondyloartritis) that has not responded well enough to conventional

Technology appraisal guidance Published September 2016

Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA406)

Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (NSCLC) in adults

Technology appraisal guidance Published September 2016